Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy
Public ClinicalTrials.gov record NCT01002950. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Multicenter, Randomized, Double-Masked, Placebo-Controlled, Dose Escalation, Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACU-4429 in Subjects With Dry Age-Related Macular Degeneration (Geographic Atrophy)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the investigational drug ACU-4429 in subjects with geographic atrophy.
Study identification
- NCT ID
- NCT01002950
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 72 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2009
- Primary completion
- May 31, 2012
- Completion
- Sep 30, 2012
- Last update posted
- Mar 10, 2014
2009 – 2012
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Retinal Consultants of Arizona | Phoenix | Arizona | 85014 | — |
| Retina-Vitreous Associates Medical Group | Beverly Hills | California | 90211 | — |
| Covance Clinical Research Unit, Inc. | Daytona Beach | Florida | 32117 | — |
| National Ophthalmic Research Institute | Fort Meyers | Florida | 33912 | — |
| Covance Clinical Research Unit, Inc. | Honolulu | Hawaii | 96813 | — |
| Kresege Eye Institute | Detroit | Michigan | 48201 | — |
| Associated Retinal Consultants, P.C. / William Beaumont Hospital | Royal Oak | Michigan | 48073 | — |
| New York Eye and Ear Infirmary | New York | New York | 10003 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| Black Hills Regional Eye Institute | Rapid City | South Dakota | 57701 | — |
| Covance Clinical Research Unit | Austin | Texas | 78752 | — |
| Covance Clinical Research Unit, Inc. | Dallas | Texas | 75247 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01002950, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 10, 2014 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01002950 live on ClinicalTrials.gov.